Quarterly revenue growth at/above 30%+ total / 40%+ oncology
גבוה פלטפורמת בדיקות גנטיות מבוססת cfDNA; המנוע המרכזי הוא Signatera למעקב MRD אחרי אבחון סרטן.
מועמדת ל'מכונת צמיחה' באבחון מולקולרי — אטרקטיבית אך עם סיכון של ולואציה פרמיום.
- מצב התזה
- אטרקטיבית מבנית ומבוססת-עדות, אך רגישה-לולואציה ולא מנוטרלת-סיכון במלואה.
- תפקיד בתיק
- מועמדת לקומפאונדר איכותי/צומח באבחון, עם סיכון של ולואציה פרמיום.
- מסגרת פעולה
- החזקה / מעקב (Hold / Monitor)
- טריגר לסקירה
- דוחות, עדכון משלם, חשיפת מדד Signatera, עדכון מתחרה MRD או השקה/תמחור ביפן.
- גישת הערכה
- Scenario-based; no single price target
מצריך סקירה אנושית שווי / משקל: לא מחושב
מה חייב לקרות
- Signatera retains MRD leadership
- Payer breadth, repeat testing, ASP, margins and cash flow strengthen
- Operating leverage emerges; dilution moderates
- Premium valuation supported through execution, not multiple alone
מה יכול לשבור את התזה
- Sharp and durable Signatera / oncology growth deceleration
- Material reimbursement restriction, commercial-payer rejection or ASP compression
- Clearly superior competitor clinical/economic performance with share loss
- Structural gross-margin decline or failed operating leverage at scale
- Cash flow turns negative again or dilution accelerates materially
- Management disclosure/credibility worsens enough to prevent monitoring
- Premium valuation persists despite a weaker thesis
הקטליסטים הבאים
Disclosure of Signatera-specific revenue, oncology ASP or franchise margin
גבוה Japan CRC commercial launch and reimbursement pricing announced
גבוה Major commercial payer positive coverage for Signatera across solid tumors
גבוה Gross margin holds >=64% or improves toward 66%+
גבוה Competitor MRD data (Guardant, Exact/Abbott, Personalis, Tempus, NeoGenomics)
גבוה הסיכונים המרכזיים
Valuation already prices in years of successful execution
Signatera oncology growth slows materially
Signatera realized ASP and payer-specific rates not disclosed; economics may be weaker than implied
MRD competitors achieve stronger evidence or payer traction
Operating expenses grow faster than revenue; operating leverage fails
Payer policies/guidelines turn technology-neutral and price-sensitive
GAAP profitability remains distant; positive cash flow is management-defined
KPI למעקב
- FY2025 revenue
- $2.306B — +35.9%
- Q1 2026 revenue
- $696.6M — +38.8%
- FY2025 oncology tests
- ~800.8K — +51.6%
- Q1 2026 oncology tests
- ~258.9K — +54.4%
- Gross margin
- 64.7% — FY2025 and Q1 2026; 2026 guidance 64%-66%
- FY2025 net loss
- $(208.2)M — GAAP losses persist; positive cash flow is management-defined
- Q1 2026 net loss
- $(85.1)M
- Implied revenue per reported test
- ~$748 (Q1 2026) — directional; up from ~$580 FY2024; not Signatera-specific ASP
כללי פעולה — מסגרת, לא המלצה
הוספה (Add)
- Require a meaningful valuation reset with intact thesis, OR materially stronger evidence on Signatera, reimbursement, margins, cash flow or competition
- Never add because price fell alone
החזקה (Hold)
- Thesis and execution remain intact
- Valuation demanding but not clearly irrational
- Position size appropriate; unresolved gaps remain monitorable
קיצוץ (Trim)
- Expectations or position size materially exceed evidence
- Growth slows while the multiple stays high; competition/expenses/dilution rise
- Trim can be risk management, not thesis rejection
יציאה (Exit)
- Signatera growth, reimbursement, ASP, competitive position, margin or cash-flow thesis deteriorates materially while valuation stays premium
שאלות פתוחות
Signatera-specific revenue, ASP and oncology gross margin
קריטי Medicare / commercial / self-pay payer mix and denial rates
גבוה Repeat testing and tests per oncology patient
גבוה Signatera MRD market share by indication
גבוה Guardant Reveal and Exact/Abbott Oncodetect adoption
גבוה Tumor-informed vs tissue-free performance and workflow by indication
גבוה Japan pricing, launch pace and uptake
בינוני Operating leverage, normalized free cash flow, SBC and dilution
גבוה Growth and margin assumptions embedded in the premium valuation
קריטי מקורות בריפו
נתיבים בריפו (מקור האמת) — לעיון, לא קישורים פעילים:
ai-context/company-briefs/ntra-he.md companies/ntra/dashboard.mdcompanies/ntra/thesis.mdcompanies/ntra/ic-memo.mdcompanies/ntra/risks.mdcompanies/ntra/catalysts.mdcompanies/ntra/competition.mdcompanies/ntra/monitoring/README.mdcompanies/ntra/working-notes.md
Derived from companies/ntra/ — the repo is the source of truth. No price targets, no buy/sell recommendation. Signatera is post-diagnosis MRD, not screening; do not conflate with Galleri. Medicare coverage is criteria-based and indication-specific; commercial coverage is separate and heterogeneous. The MIBC FDA CDx approval does not generalize to every Signatera use. The moat is real but contested.